The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Reuben Dawkins, CEO of Link Biologics, a company developing protein biologics to treat inflammatory and degenerative conditions. Link is currently developing treatments for Dry Eye… Read More
The US Food and Drug Administration (FDA) has granted Fast Track Designation for a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). CTx001, developed by biotechnology company Complement Therapeutics, is a novel adeno-associated virus (AAV)-based gene therapy designed… Read More
The US Food and Drug Administration (FDA) has cleared Complement Therapeutics’ Investigational New Drug (IND) application for CTx001, the company’s lead gene therapy candidate. The IND clearance enables initiation of the Opti-GAIN Phase I/II clinical trial in patients with geographic atrophy (GA) secondary to age-related macular degeneration… Read More
Sanofi’s investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration (AMD) has been granted fast track designation by the US Food and Drug Administration (FDA). Sanofi’s SAR402663 is currently being evaluated in a Phase I/II clinical trial for patients with neovascular AMD. Read More
The Scottish Medicines Consortium (SMC) has approved Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD). It is the first licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU and the UK and has an initial… Read More
The US Food and Drug Administration (FDA) has granted clearance for Endogena’s Investigational New Drug (IND) application for EA 2351, a potential treatment for geographic atrophy (GA). GA is an advanced form of age-related macular degeneration (AMD). The first-in-human study is set to commence in 2024. Read More
Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA). Boehringer Ingelheim and CDR-Life entered a licensing agreement in May 2020 and announced the… Read More
New research suggests that age-related macular degeneration (AMD) decreases an essential fatty acid, preventing the formation of a class of protective molecules and reducing repair potential – a discovery that may open new therapeutic avenues for AMD. The study shows that AMD decreases peripheral retinal docosahexaenoic… Read More
The US Food and Drug Administration (FDA) has approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The new complement C5 inhibitor is the only approved GA treatment with a statistically significant reduction in the rate… Read More
Aviceda Therapeutics has dosed the first patient in its Phase II SIGLEC trial investigating AVD-104 as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is a novel glycan-coated nanoparticle, supported by a strong pre-clinical in vivo efficacy and safety profile. Read More
In the UK, a University of Manchester-led team of scientists has discovered that the most common form of adult blindness is probably caused by a failure of at least one of five proteins to regulate the immune system. The breakthrough could one day herald the development of transformative treatments for… Read More
